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It’s Time
Open the window of
your mind.
Throw out the trash
Let in fresh air and
ideas
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Extracts from Helsinki Protocol - 1
The World Medical Association (WMA) has developed the Declaration of
Helsinki as a statement of ethical principles for medical research involving
human subjects, including research on identifiable human material and data.
The Declaration of Geneva of the WMA binds the physician with the words, “The
health of my patient will be my first consideration.”
International Code of Medical Ethics declares that, “A physician shall act in the
patient's best interest when providing medical care.”
Physicians must immediately stop a study when the risks are found to outweigh
the potential benefits or when there is conclusive proof of positive and
beneficial results.
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Extracts from Helsinki Protocol- 2
In the treatment of a patient, where proven interventions do
not exist or have been ineffective, the physician, after seeking expert
advice, with informed consent from the patient or a legally
authorized representative, may use an unproven intervention if in
the physician's judgement it offers hope of saving life, re-establishing
health or alleviating suffering. Where possible, this intervention
should be made the object of research, designed to evaluate its
safety and efficacy.
In all cases, new information should be recorded and, where
appropriate, made publicly available.

THIS IS THE PURPOSE OF THIS LECTURE
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What is Carnitine Transporter

It’s a tonguetwister.
Just remember
the first point.

Needed for transfer of long‐chain fatty acids across the inner mitochondrial
membrane for its utilisation/ oxidation.
Requires enzymes and transporters that accumulate carnitine within the cell
(OCTN2: carnitine transporter), conjugate it with long chain fatty acids (CPT1:
carnitine palmitoyl transferase 1), transfer the acylcarnitine across the inner
plasma membrane (CACT: carnitine ‐acylcarnitine translocase), and conjugate the
fatty acid back to Coenzyme A for subsequent beta oxidation (CPT2: carnitine
palmitoyl transferase 2).
◦ Primary Carnitine Deficiency and Cardiomyopathy,
Lijun Fu et al, http://dx.doi.org/10.4070/kcj.2013.43.12.785
◦ Disorders of carnitine transport and the carnitine cycle, Nicola Longo et al, Am J Med Genet C
Semin Med Genet. 2006 May 15; 142C(2): 77–85
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Deficiency result of Carnitine Transporter
Deficiency of the OCTN2 carnitine transporter causes primary
carnitine deficiency, characterized by increased losses of carnitine in
the urine & decreased carnitine accumulation in tissues.
Possible Presentations:
1. Skeletal and CARDIAC

MYOPATHY

2. Hypoketotic hypoglycemia and hepatic encephalopathy
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Management that usually
but NOT always, works
Treatment for carnitine consists in a low‐fat diet
supplemented with medium chain triglycerides that
can be metabolized by mitochondria independently
from carnitine, (mega-dose) Carnitine supplements,
& avoidance of fasting and sustained exercise.
◦Mitochondrial Cardiomyopathy, Deborah E. Meyers et al,
Texas Heart Inst J. 2013; 40(4): 385–394
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Carnitine Transporter Deficiency
Cardiomyopathy
Carnitine Transporter Deficiency induced cardiomyopathy is a rare
autosomal recessive genetic disorder, characterized by plasma
membrane carnitine transport defect, impairing uptake and
oxidation of long chain fatty acids at the mitochondrial level
◦ A. Cano et al, Ped. Cardiol. 2008; 29(1): 163-165

This may cause oedema, sometimes therapy resistant heart failure,
metabolic acidosis, hypoglycaemia, muscle weakness.

Investigations show normal PFT, ECG with giant T waves with
prolonged QT intervals, subnormal blood carnitine levels and highly
abnormal Echo Cardiogram
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The case of QAB: severe carnitine
transporter deficiency cardiomyopathy
QAB was diagnosed at Aga Khan University (AKU) Hospital, Karachi, as a
progressive case of Congenital Cardiomyopathy in childhood due to of Carnitine
Transporter Deficiency.
Family History: 2 pre-teen brothers earlier succumbed to this disease. One sister
and one brother seem to have been spared. QAB affected. He had been on heart
failure medications and mega dose L-carnitine as per prevailing medical practice,
which had helped to prolong his life till 16 years with relapse and remissions. He
exhibited slowly deteriorating heart failure, in spite of optimum recommended
carnitine supplementation plus heart failure therapy.
Presented in Jan. 2015 with LVEF 20-25% as recorded at AKU, Fortis C-DOC
Hospital & NHI, with breathlessness on climbing 2 flights of stairs.
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Test for
Diagnosis
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Pre-therapy PFT
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EKG

Major
section of
COA of MSC
used
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Treatment given to QAB by us
Mega dose L-Carnitine + CHF therapies continued as at AKU Hosp.
(Dr. M Atiq) plus salt restricted non-strainous life style.
HBOT 1.5 ATA with 100% Oxygen, 15 minutes to dive plus 15 minutes
to surface plus 60 minutes at full pressure x 40 sessions. After 20
sessions, we proceeded to transplant Stem Cell.
◦ OUR HYPOTHESIS: The heart is merely starving and is showing secondary
effects of this. Carnitine Transporters are proteins, majority synthesized in the
LIVER. Why not help the liver also?
◦ Hence, we gave 1/3rd dose of fresh MSC calculated/kg body weight,
in Coronary arteries to help the weakened heart & the rest 2/3rd in the liver
to enhance liver Carnitine Transporter manufacture.
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Serial
LVEF
Data

Table 1: LVEF data from Echo-Cardiogram record.
Date: Y/M/D
Where Done
2006/01/13
AK Univ. Hosp. Karachi
2006/12/29
AK Univ. Hosp. Karachi
2007/02/26
AK Univ. Hosp. Karachi
2007/06/04
AK Univ. Hosp. Karachi
2008/01/14
AK Univ. Hosp. Karachi
2008/05/05
AK Univ. Hosp. Karachi
2008/08/04
AK Univ. Hosp. Karachi
2009/05/20
AK Univ. Hosp. Karachi
2009/10/14
AK Univ. Hosp. Karachi
2010/05/26
AK Univ. Hosp. Karachi
2010/12/31
AK Univ. Hosp. Karachi
2011/02/09
AK Univ. Hosp. Karachi
2011/08/22
AK Univ. Hosp. Karachi
2012/02/20
AK Univ. Hosp. Karachi
2013/01/02
AK Univ. Hosp. Karachi
2013/04/03
AK Univ. Hosp. Karachi
2013/04/15
AK Univ. Hosp. Karachi
2014/10/22
AK Univ. Hosp. Karachi
2015, January
Initial at Fortis C-DOC Hospital, Delhi
2015/02/31
After HBOT+SCT, Natl.Heart Inst,Delhi
2015 July
AK Univ. Hosp. Karachi
2016 January
Post Procedure, NHI, Delhi
2017 January
AK Univ. Hosp. Karachi
2018, January
AK Univ. Hosp. Karachi

LVEF %
30
59
60
60
58
34
47 Dx done
50
54
55
70
56
50
55
30
32
26
30
20 1st Procedure
35 Post-Proc.
55
55 2nd Procedure
84 Stable
55 Neglecting Rx still LVEF Ok
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Stem Cell delivery to QA
Heart & Liver as shown

HEART

LIVER
16

Outcome of therapy (Jan 2015 )
LVEF went up from 20% to 35% (Fortis C-Doc Hospital, Delhi: immediate HBOT action) within 6
weeks, by February 2015

LVEF went up to 55% (delayed SCT Effect) by Mid 2015.
January 2016, LVEF maintained at 55%. (Normal)
1st Booster dose of HBOT + SCT given as before.
January 2017, LVEF reached 80 – 85% (Maximum normal)
Boy felt so good, he became like any naughty boy of his age, indulged in by his father who had
already lost two sons to the disease.

He neglected regular medications, diet control & life style guidelines to a fair degree.
January 2018, LVEF still at 55%, doing well and enjoying normal life.
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Discussion 1
This being a treatment failure case of carnitine transporter deficiency induced
cardiomyopathy, who appeared to be in the last lap of his lifespan, we decided to use
desperate measures under the provisions of Helinki Protocol Para 35.
Carnitine is a naturally occurring hydrophilic amino acid derivative, produced endogenously in
the kidneys and liver and derived from meat and dairy products in the diet.
Cannot easily enter mitochondria and get oxidized for energy production and formation of
ketones for brain function.
◦ Fernando Scaglia (2014) Carnitine Deficiency

Carnitine plays an essential role in the transfer of long chain fatty acids into the mitochondria for
beta-oxidation.
◦ Longa N, Amat C, Pasquali M (2003) The OVTN2 carnitine transporter and fatty acid oxidation.
Membrane transporter disease, pp. 161-174.
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Discussion 2
We chose to use HBOT, prior to use of stem cell therapy
based on the work of Diaj-Barbosa et al. in early 2000s.
They showed that stem cell therapy in the middle of HBOT,
gave a greater benefit than either therapy alone.
◦ JL Diaz-Barbosa & FJ Morales; (July 2003) 3rd Int. Symposium on Cerebral Palsy and the Brain Injured
Child. Fort Lauderdale, Florida.
◦ JJ Catherine, Tonseth KA, Utheim TP (2017) Cultured epidermal stem cell in regenerative medicine. Stem
Cell Res Ther 8(15): 155.

We followed similar protocol with on-site transplantation
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Conclusion:
Carnitine Transporter Deficiency Cardiomyopathy
No adverse reaction from our treatment protocol, even after 3 years.
It is difficult to quantify the relative degree of help obtained by this
previously non-responder case, from HBOT, stem cell therapy and
both given together.
Not enough cases per center to do a DBPCR Trial. Hence, going by this
single safe and effective case study record, we propose to follow the
same protocol for future cases if any, till we have more data.

We are also open to an international collaborative study
20

REGENERATIVE THERAPIES
A NEW APPROACH IN MEDICINE
using HBOT + Stem Cells.
We have many more cards up our
sleeve, but that is for the next time
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Our Philosophy in NDD is to use:
LIFE STYLE MANAGEMENT

Multimode approach regulated by INDIVIDUAL NEED only.
◦ Comprehensive individual need based Standard Therapies: COMPULSARY
◦ Biomedical need-based approach, using special diets + micronutrients, with regular follow up
adjustments as per age, sex, weight, need, etc. + drugs:
IF NEEDED
◦ HBOT, based on SPECT 3D Fusion Scan: IF NEEDED
◦ rTMS with NFB , based on SPECT 3D Fusion Scan: IF NEEDED
◦ Sensory Integration Therapy, based on Clinical Findings: IF NEEDED
◦ Ayurveda / Unani based brain repairing agents and antivirals: IF NEEDED
◦ VERY SELECTIVE cases for Stem Cell Therapy when no approved available therapy is giving
desired results after 4 to 5 years age, done as per Helsinki Protocol
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Special Education, ABA, Speech Therapy
Cognition, behaviour, memory, speech, oro-motor
skills, etc. are mainly controlled by Prefrontal lobe,
Basal Ganglia, Anterior Cerebellum, Thalamus,
lower Parietal lobe
These therapies polish up the remnant neuronal
functions in the inflamed hypoxic brain to bring
out the best possible improvement in a child.
However, these therapies cannot resolve / repair /
regenerate the damaged brain areas (Penumbra)
involved in Inflammatory HIE.
HBOT +/- SCT may, to a good extent
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OT/PT, Sensory Integration Therapy
Hyper-sensitivity to sensations like sound,
light, touch, hyperactivity, high selective
muscle tone, aggressive behavior, cognition &
behavior are controlled by Frontal and
Prefrontal lobe, Cerebellum and basal
Ganglia.
Physical Therapies including S/I may polish up
the remnant neuronal functions in the
remaining normal areas in these areas of
brain to bring out the best possible
improvement in the child.
However, they cannot regenerate the
inflamed HIE lesions of damaged brain for
augmented benefits.
HBOT +/- SCT may, to a good extent
24

Sensory Integration Laboratory
augments effects of OT

Sensory Integration Therapy deserves special mention. It work to an extent we
had not expected. The colour-changing glass fibre strands, the softly vibrating
mattress, moving laser light show, bubble columns and soothing music helps
calm down the child to enhance, concentration & reduce Attention Deficit
Hyperactivity Disorder.
HBOT helps augment ALL these functions by healing the brain to a good
extent.
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Arts & Crafts and Group Activities
These group activities enhance
socialization, eye-hand and mental
concentration, learning to share and
enjoy together
These are some of our basic instincts
and abilities, mostly fine-tuned by
the basal ganglia, cerebellum,
temporal lobe, and practically all
sensory motor and emotional areas.
Inflammatory HIE in these areas
reduces above skills.
However, they cannot regenerate
the inflamed HIE lesions of damaged
brain for augmented benefits.
HBOT +/- SCT may, to a good extent
26

Extramural Activities to train them to live and perform in open society

Planning Trustees
National Spokesperson inaugurating the run
Marathon success.
Our Team
winners

Ambulance on standby
Felicitating the
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How HBOT works: From high O2 to Cytokine
actions
You don’t need
to know why
the Laptop
functions.
But you must
know what it
can do.

SR Thom, Plastic
and
Reconstructive
Surgery.
127():131S141S, JAN 2011
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Defining Stem cells (Incl. Mesenchymal)
Called Master Cells of the body.
◦ Undifferentiated cells. Have the ability to divide and differentiate into other 200 cell types.

Stem cells distinguished from other cell types by 2 important characters
◦ Stem cells are unspecialized cells capable of renewing themselves through cell division, sometimes after long
periods of inactivity.
◦ Under certain physiologic or experimental conditions, they can be induced to become tissue or organ specific
cells with special functions, like cartilage, liver tissue, heart muscle, pancreatic tissue, nerve tissue, blood cells
etc.

Mesenchymal cells are HLA antigen-deficient stem cells
◦ https://stemcells.nih.gov/info/basics/1.htm (last accessed 1st May 2018)
◦ https://medlineplus.gov/stemcells.html (last accessed 1st May 2018)
◦ Human mesenchymal stem cells - current trends and future prospective; Umrao Ullah et al, Biosci Rep. 2015;
35(2): e00191
◦ A Concise Review on the Use of Mesenchymal Stem Cells in Cell Sheet-Based Tissue Engineering with Special
Emphasis on Bone Tissue Regeneration; Stem Cells International, Volume 2017, Article ID 2374161, 13 pages
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Dawn of a new era, using rHBOT / mHBAT
with or without stem cells
Peak
effect:
HBOT
4-6 mth
SCT
6-24 mth

• Refer also to:
Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in
experimental traumatic brain injury, Run Zhang et al; Journal of Neuroinflammation; 2013: 10:871
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Totipotent (embryonic) Stem cells
CAN POTENTIALLY MAKE ANY PART, maybe even clone.

X

Generally not permitted due to ethical, moral, legal restrictions.

Small risk of cancer / tumor formation after 4 to 5 years
LONG TERM safety unknown though potency very good.
GVHD (Graft versus host disease) rarely seen but what happens at micro level is unknown;

Small stock.
Needs Culturing and often Cell Manipulation to obtain therapeutic dose of desired specific stem cell
line.
◦ In culture, after about 3 passages, senescence or Genetic Micro-Array changes (mutation) may occur.
◦ Donor’s tissue antigen start to appear
◦ Their long term effect not fully studied and published.

WE LIKE TO STAY AWAY FROM IT.
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Bone Marrow Stem cell (BMSC)
Bone marrow derived mononuclear cells (high % of CD34+ but low
Mesenchymal Stem cells) with no chemical added, has stood test of
time (> 5 decades) as reasonably effective & safe with virtually no
risk of tumor formation.

Though adequate stock available, there remains a problem with
senescence of the stem cells inside the recipient body, hence efficacy
less if donor is aged > than 12 years.
Antigen matching needed if allogenic donor blood used.
No infection, no allergy, no GVHD, if used in same patient.
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BMSC Protocol for Stem Cell therapy
Requirement: > 2 - 4 million viable stem cells/ kg body wt, or more as per severity & # of sites
Practical: one site on Bone marrow prick yields 1.2 - 2 ml Marrow, rest is oozing blood: useless.
◦ Usually, using many pricks and twisting the needle tip, we get 60 ml of marrow

Donor age > 10 years, may have stem cells that do not last & multiply long enough in body to be
optimally useful.
◦ Influences of age-related changes in mesenchymal stem cells on macrophages during in-vitro culture;
Yuan Yin et al; Stem Cell Research & Therapy (2017) 8:153

Culture (passages) up to 2 yield true antigen-less copies. After 3 to 4 passages, donor HLA
antigens start to appear. NOW, tissue matching recommended as we need a lot of stem
cells/patient, even in a child.
Storage: kept at -180C & transported at -80C, still 10 - 40% will degenerate. Overages needed
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Peripheral Blood Stem cells
Good for autologous (self-) use for treating acquired lesions.

Peripheral Blood has Stem Cells but the pool is very small. Collected from blood
by apheresis (as we sometimes do for platelets).
The blood stem cell pool may be temporarily enhanced by injection of specific
chemicals to make the marrow release more stem cells.
CAUTION FOR ALLOGENIC USE: Micro-array genetic changes after 3 passages on
culture not yet studied. Most cells will be CD34+ type.

If collected at age > 12 years, the problem of senescence comes in since these
cells do not multiply long enough inside the recipient body.
Long term safety and potency is being studied by other researchers.
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Cord Blood Stem Cells
Autologous
If used in same patient, very safe and quite effective. BUT, small stock. Must be
cultured to get optimum quantity.
Long term viability issues after years of storage, even at -181C.
Cannot be used in genetic diseases in same patient as his SCs carry same defect.
Donor Pool
Pooled cord blood generally easily available.
◦ Tissue match recommended for safety.
◦ Proper handling, maintenance of sterility, donor history, infectious disease profile, etc. to be
ensure stringently.
◦ Antigen matching needed if allogenic donor blood used.
◦ No infection, no allergy, no GVHD, if used in same patient.

UCBSC sources must comply with AABB, etc.
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Umbilical Cord Tissue stem cells (UCTSC)
Wharton’s Jelly, Somewhat similar to Prochymal®
The umbilical cord and placenta contains a filler tissue called
Wharton’s Jelly comprising mostly the primitive
Mesenchymal Stem Cells and a negligible population of
hemopoietic Stem Cells (CD34+). Together, they offer a
wider range of applications than either alone.
Relatively easily available after proper check-up of viability,
infection profile, and standardization HLA etc. analysis).
Donated UCTSC appears useful in genetic diseases

UCTSC sources must comply with AABB, etc.
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Minimal Criteria for MSC
Adherent to plastic

Surface antigens present:
◦ More than 95 % expression of CD-105, CD-73 & CD-90
◦ MSCs must NOT express (less than 2%) CD-14, CD-11b, CD-79a, CD-19, CD-34,
CD-45 and HLA-DR)
◦ Must be capable of differentiating into various tissue types
◦ Naked cells that, till two passages of in-vitro culture, do not acquire the donor
antigen. If obtained from umbilical cord Wharton’s Jelly, enough material
obtained to avoid more than 2 passages.
Int. Society for Cellular Therapy, Cytotherapy, 2006, Vol.8, No.4, Pg 3-15-317)
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Mesenchymal Stem Cells (MSC)
Specific stem cells that closely resembles Embryonic Stem Cells
◦ These MSCs undergo Cell Fusion with injured resident Stem Cells.
◦ Resident stem cells in coordination with infused MSC helps to develop new
cell types and repair injured ones.
◦ Needed to repair / replace a tissue type; e.g.:
◦
◦
◦
◦
◦
◦
◦

Brain / nerve tissue in brain injury / inflammation
Heart muscle tissue in AMI
Pancreatic b cells in Diabetes
Liver tissue in Cirrhosis; can overcome insulin resistance
Lung tissue in COPD
Cartilage tissue in Osteoarthrosis
Repair/Regeneration in genetic diseases like Thalassemia, DMD, Carnitine Transporter Deficiency CHD
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Benefits of MSC
Promising therapeutic effects even though the transfused cells were,
if at all, only barely detectable in the injured organs.
Secretes factors (Interleukins and Cytokines) that actively modulate
debilitating local inflammatory reactions.

Reduces apoptosis, and fibrotic tissue remodeling
Recruits resident regenerative cells to contribute towards the
beneficial effects
◦ A. I. Caplan and J. E. Dennis 2006; E. M. Horwitz and W. R. Prather 2003.
◦ Treatment of stroke significantly reduces apoptosis within the
peri-lesioned area, (J. Chen et al 2003).
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Redox Regulation by Stem Cells & HBOT
The low level of H2O2 in quiescent hematopoietic stem cells (HSCs) contributes to maintain their
stem-ness, whereas a higher level of H2O2 within HSCs or their niche promotes differentiation,
proliferation, migration, and survival of HSCs or stem/progenitor cells.
Excess amounts of ROS create an inflammatory and oxidative micro-environment  cell damage
and apoptosis of stem and progenitor cells.
HBOT promotes progenitor cell expansion and mobilization from BM, leading to reparative
neovascularization and tissue repair in pathophysiological states such as aging, atherosclerosis,
heart failure, hypertension and diabetes
Understanding these molecular mechanisms will lead to the development of novel therapeutic
strategies.
◦ Adapted from Redox regulation of stem/progenitor cells and bone marrow niche; Norifumi Urao,
Masuko Ushio-Fukai, Dept of Pharma, Center for Lung and Vascular Biology, Center for Cardiovascular
Research; Univ. Illinois, Chicago; Free Radic Biol Med. 2013 January ; 54: 26–39
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S.Cs regulate Cytokines just like HBOT
Stem cells down-regulate pro-inflammatory Cytokine
after injury and reverse the cytokine effect in 2 to 3
days of injury
◦Anti-inflammatory and immunomodulatory mechanisms
of mesenchymal stem cell transplantation in experimental
traumatic brain & immunomodulatory mechanisms of
mesenchymal stem cell transplantation in experimental
traumatic brain injury;
◦ Run Zhang et al; J. of Neuro-inflammation; 2013: 10: 871
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Mobilisation of BM Stem Cells
HBOT mobilizes bone marrow derived-stem/progenitor cells by a free radical
mediated mechanism
Post-treatment values of CD34+, CD45-dim leukocytes were always 2-fold
greater than the pre-treatment values.
The authors concluded that putative progenitor cell mobilization is higher with
HBOT, and all newly mobilized cells exhibit higher concentrations of an array of
regulatory proteins.
◦ CD34+/CD45-dim stem cell mobilization by hyperbaric oxygen – changes with oxygen dosage;
SR Thom et al; Stem Cell Res. 2014 May; 12(3): 638–645
◦ Efficient Homing of Multipotent Adult Mesenchymal Stem Cells Depends on FROUNTMediated Clustering of CCR2; Fikru Belema-Bedada at al: Cell Stem Cell, Volume 2, Issue 6, 5
June 2008, Pages 566-575,

42

Composition of Adult Stem cells
CD 34+ cells are hemopoietic stem cells. A primitive subset - CD133+ cells
differentiate into neurons.
Mesenchymal stem cells are Primitive Cell progenitors (comparable to
embryonic stem cells). They can release Glial derived neurotrophic factor
(GDNF). GDNF can rescue neurons from a lack of oxygen and help stimulate the
repair of white matter in the brain.
CD34+ stem cells can also release Neurotrophin 3 (NT-3), Nerve Growth Factor
(NGF) and Brain Derived Neurotrophic Factor (BDNF), which can stimulate the
growth of new neurons. They help balance the immune system and
autoimmune disorders, relax the artery walls which promotes improved blood
flow. Cerebral palsy or TBI is characterized by white matter damage and is the
best responder to adult stem cell treatments.

Biological effects of Stem Cells
Adult MSCs are capable of dividing into one of several mesenchymal phenotypes
such as osteoblasts, chondrocytes, myocytes, marrow stromal cells,
tendon‐ligament fibroblasts, and adipocytes.
These MSCs secrete a variety of cytokines and growth factors that have both
paracrine and autocrine activities. They have bioactive factors suppress the local
immune system, inhibit fibrosis (scar formation) and apoptosis, enhance
angiogenesis, and stimulate mitosis and differentiation of tissue‐intrinsic
reparative or stem cells. These effects, which are referred to as trophic effects,
are distinct from the direct differentiation of MSCs into repair tissue. Several
studies which tested the use of MSCs in models of infarct (injured heart), stroke
(brain), or meniscus regeneration models examples of MSC‐mediated trophic
effects in tissue repair.
◦ Mesenchymal stem cells as trophic mediators; A. I. Caplan et al, J. Cell. Biochem. 98: 1076-1084, 2006
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Spastic paresis after perinatal brain damage in rats is
reduced by human cord blood mononuclear cells
Therapeutic potential examined for human umbilical cord blood derived mononuclear cells
containing multipotent stem cells to facilitate motor recovery after cerebral hypoxic-ischemic
damage in neonatal rats.
◦ Left carotid artery ligation followed by resuscitation was done.
◦ Histologic and immuno-histochemical analysis on postnatal d 21 revealed that neonates developed
severe cerebral damage after the hypoxic-ischemic insult.

After transplantation of human umbilical cord blood derived mononuclear cells, spastic paresis
was largely alleviated, resulting in a normal walking behaviour.
◦ This effect was accompanied by the fact that mononuclear cells had entered the brain and were
incorporated around the lesion without obvious signs of trans differentiation.

Their study demonstrated that intraperitoneal transplantation of human umbilical cord blood
derived mononuclear cells in a rat model of perinatal brain damage leads to both incorporation
of these cells in the lesioned brain area and to an alleviation of the neurologic effects of cerebral
palsy as assessed by footprint and walking pattern analysis.
◦ Carola Meier et al, Pediatr Res 59: 244–249, 2006
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Figures in Carola Meier et al
A. Schematic representation of the distribution of human cells in the lesioned
hemisphere. HLA-DR-positive cells (green) are detected in the area of hypoxic-ischemic
lesion. Contralateral hemisphere devoid of human cells.

B. HLA-DR-positive mononuclear cells (green) are located within a scaffold of GFAP-(+)
astrocytes (red) in the area of the hypoxic-ischemic lesion.
C. Non-lesioned parts of the brain, with absence of
inflammatory and apoptotic events are devoid of human
cells (absence of green fluorescence).
D. Lesioned areas of the brain of animals that did not receive
transplantation of human cells are devoid of
HLA-immunostaining. Note absence of green
(HLA-staining) within the red scaffold of GFAP-positive rat
astrocytes.
1. Carola Meier et al, Pediatr Res 59: 244–249, 2006

Intraperitoneal transplantation of
mononuclear hUCB-derived cells resulted in a
specific homing of these cells into CNS and
incorporation around the lesioned area
46

Donor & Host Stem Cell Communication
Donor Stem Cells seek out Host Stem Cells
(Chemotaxis). They adhere, not fuse, to
each other
Donor cell shares corrective genetic codes to
damaged host stem cells while Host stem cell
shares information of host cell antigens
Both now normal part of same body
Khan showed it in AMI cases

EXCHANGING GIFTS

◦ Oxygen and oxygenation in stem-cell therapy for myocardial infarction;
Mahmood Khan et al; Life Sciences, 2010: 87(9-10(L 269-274
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Synergism of HBOT + Stem Cell Therapy

48

HBOT pre-treated Stem Cell therapy + HBOT Neuro. cases do
better than similar groups given no pre-treatment HBOT
34 cases: M=13, F=21; Dx: HIE (n=29), Craniocephalic trauma (n=2), Motor vehicle trauma (n=1),
Motor vehicle Pedestrian trauma (n=2) TBI

Group 1: n-18; pre-treated with 10 HBOTs  Stem Cells  48 more HBOT sessions
Group 2: n=16; Stem Cells  48 HBOTs
Results:
◦ Group 1 had faster & better response with the 1st signs of improvement coming after mean 2.5 weeks
in GMFM, Speech, Attention, Function
◦ Group 2 had similar response but after mean 4.3 weeks

“The results may well be due to the synergistic effects of HBO followed by stem cell therapy. It is
believed that stem cells are attracted to neural sites with neural sites with increases vascularity
and nutrient rich environment which compensates or aids in repair of neurological damage
◦ Stem cell therapy and HBO for brain-injured children and cerebral palsy; J L Diaz-Barbosa & F J
Morales; Proc. 3rd Int. Symp. For CP an the Brain-Injured Child, July 2003; Fort Lauderdale, FL, USA
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Higher tissue O2 & Stem Cells in AMI
AMI  Deprivation of O2 & nutrients to heart due to blocked coronaries

O2 required for constant energy demands of contracting heart, role in the
regulation of heart function. However, sudden reperfusion oxygenation of the
ischemic myocardium can be injurious.
Results from these studies demonstrate the importance of tissue oxygen in the
application of stem-cell therapy to treat CAD.
The transfer of gene products from injured cells may explain stem cell functional
& phenotypic changes without the need of trans-differentiation into tissue cells.
Transfer of gene products from stem cells may reprogram injured cells to site of
injury
◦ J. Int. Soc. Nephro, tissues; 2010; 78(9): 838-848
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Requirements of transplanted stem cells
Land unprepared.
Cant expect a good crop
Land prepared. Expect a better crop
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What is Diabetes?
Diabetes is a not a simplified high blood sugar disease. It is a dysfunctional disease of protein, fat
and carbohydrate metabolism, endothelial inflammation and other complications in the CVS,
CNS, Kidneys, NASH, Foot, DPN, etc.
◦ Bl. Sugar is just an economic test and we interpolate its results for a guess at what is happening in the
WHOLE body.

T1DM: Direct insulin deficiency relative to body needs

T2DM: relative deficiency of insulin activity to metabolise oxydisable foods to release their
energy for cell and body needs.
Hyperactivity of antagonistic / counteracting hormones like excessive thyroxine, steroids,
somatostatin, catecholamine, etc.
Correct treatment mandates a correct etio-pathological diagnosis and a broad spectrum
approach as per need.
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C-Peptide
and Insulin
T1DM due to premature
burn out of pancreatic
b-Cells
Cause: Auto-immunity, viral infection, genetic susceptibility, toxins
Selection: If patients have Fasting C-Peptide < 0.5, FPG > 200 mg/dl,
PP > 300 mg/dl, often in spite of optimum available therapies
◦ One OHA that helps to an extent is metformin. I`t reduces Insulin dosage.
◦ Controlled need-based diet and lifestyle.
◦ HBOT starts becoming helpful.
◦ Life long blood sugar monitoring at frequent intervals and Insulin injections
are PAINFUL as only a T1DM patients knows, that, too, a child.
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Improving C-Peptide in T1DM
When Insulin requirements > 0.5 IU/Kg body weight along with other
findings as mentioned above, consider SCT under Helsinki protocol, if
the parents demand, as off-label experimental therapy.
Options
◦ Diet, life style, controlled exercise, metformin, coenzyme Q-10,
L-Carnitine
◦ HBOT + SCT
◦ Adjuvant drugs to enhance cellular regeneration & energy output
With Regenerative Therapies, C-Peptide may creep towards or even
reach normal, by 1 year in quite a few.
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Typical T1DM Long Term Follow-up
*Hasan, 20 yrs
August 2015
◦ HBA1c = 8.2%
◦ C-Peptide = 0.5 (N = 0.5 to 3.5)
◦ Anti-Diabetics used Insulin 41 U,

Mid 2017
◦ Initiated oral Anti-Diabetics
◦ HBA1c on 10/6/17 = 5.6%
◦ C-peptide on 10/8/17 = 1.5
◦ Insulin 32 U
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T2DM: relatively easy to treat with OHAs
Metformin; Broad spectrum inulin resistance reducing agent, esp. at liver and adipose tissue.
◦ Cardio-protective. Some role in NASH.
◦ All patients need it if tolerated

Pioglitazone: Similar to metformin as a insulin resistance reducer hypoglycemic agent.
◦ May be tried with full precaution, in patients without pre-existent heart disease,

Sulfonylureas: Used for increasing insulin RELEASE, NOT production, if B-cells (C-Peptide) ok
Repaglinide: Release insulin by a different pathway, used in patients with irregular meal times
Alfa glucosidase inhibitors: Reduce glucose absorption from intestines, in cases who will not
stop overeating
Gliptines: Pancreatic protector; reduce apoptosis in pancreas, for all types of T2DM
Glifozines: Enhance glucose excretion by kidneys, in cases who will not stop overeating
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SCT Therapy in DM 1 & 2 from our series.
Procedure common, but when, what, dosage,
route: THAT is the key
SCT TO PANCREAS

SCT TO LIVER
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T2DM: relatively easy to treat with OHAs
Metformin; Broad spectrum inulin resistance reducing agent, esp. at liver and adipose tissue.
◦ Cardio-protective. Some role in NASH.
◦ All patients need it if tolerated

Pioglitazone: Similar to metformin as a insulin resistance reducer hypoglycemic agent.
◦ May be tried with full precaution, in patients without pre-existent heart disease,

Sulfonylureas: Used for increasing insulin RELEASE, NOT production, if B-cells (C-Peptide) ok
Repaglinide: Release insulin by a different pathway, used in patients with irregular meal times
Alfa glucosidase inhibitors: Reduce glucose absorption from intestines, in cases who will not
stop overeating
Gliptines: Pancreatic protector; reduce apoptosis in pancreas, for all types of T2DM
Glifozines: Enhance glucose excretion by kidneys, in cases who will not stop overeating
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Our Ultimate aim:
Help as a Physician should
Dream it

◦Do it
◦Demonstrate how
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